Sun Pharma Advanced Research Company share price
NSE: SPARCBSE: 532872Pharmaceuticals & BiotechnologySmall Cap
Last close ₹171.77down ₹1.32 (0.76%)BSE ₹171.75
Share price at the NSE close on 23 Oct 2026. Previous close ₹173.09.
52-week range of traded prices to 23 Oct 2026
₹108.00Low, 23 Mar 2026₹289.00High, 8 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹5,574 Cr778th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 10 Aug 2026
- 3.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 18 May 2026
- 4.2
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the latest balance sheet's; the one a year before is not on record. The filing of 10 Aug 2026
- 118.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 10 Aug 2026
- 84.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 18 May 2026
- 0.42
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 7,97,11238.6% delivered
Results
Standalone, as consolidated accounts are on record for only 3 of the last ten years; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 10 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹40 Crdown 97.85%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹21 CrQuarter to Mar 2026: ₹1,761 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −52.6%
Revenue by year
Peak revenue ₹1,879 Cr, year to Mar 2026
Net profit by year, a loss in red
- Net profit
- Loss
Back to profit in the year to Mar 2026, ₹1,552 CrA loss in 9 of the 10 years shown
| ₹ crore | Sep 2024Filed 4 Nov | Dec 2024Filed 10 Feb | Mar 2025Filed 12 Jun | Jun 2025Filed 4 Aug | Sep 2025Filed 10 Nov | Dec 2025Filed 9 Feb | Mar 2026Filed 18 May | Jun 2026Filed 10 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13 | 15 | 27 | 10 | 8 | 8 | 1,853 | 40 |
| Net profit | −108 | −80 | −61 | −52 | −76 | −81 | 1,761 | −21 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | −837.4% | −534.6% | −224.3% | −539.7% | −966.5% | −953.5% | 95.0% | −52.6% |
Standalone. The last eight quarters. The latest is shaded.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical Research and Development, which carries all its revenue.
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −22.3% | – | – | 0.0% |
| 3 years | −13.8% | – | – | 0.0% |
| 5 years | −4.2% | – | – | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record. Earnings growth over 3 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Mutual funds holding it
10 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 9 of the 9 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- AddedAdded. Funds that held more shares than at the end of the month before.
- 4
- CutCut. Funds that held fewer shares than at the end of the month before.
- 5
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 1
| Fund | |||
|---|---|---|---|
 Motilal Oswal Nifty Microcap 250 Index FundMotilal Oswal Mutual Fund | 2,54,835 | 0.21% | ₹5.03 Cr |
 Samco Multi Cap FundSamco Mutual Fund | 47,421 | 0.43% | ₹0.94 Cr |
| Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 2,622 | 0.12% | ₹0.05 Cr |
 Groww Nifty Total Market Index FundGroww Mutual Fund | 1,665 | 0.01% | ₹0.03 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 1,236 | 0.12% | ₹0.02 Cr |
| Motilal Oswal BSE 1000 Index FundMotilal Oswal Mutual Fund | 277 | 0.01% | ₹55,000 |
 Angel One Nifty Total Market Index FundAngel One Mutual Fund | 278 | 0.01% | ₹54,820 |
 Mirae Asset Nifty Total Market Index FundMirae Asset Mutual Fund | 229 | 0.01% | ₹45,000 |
| Bandhan Nifty Total Market Index FundBandhan Mutual Fund | 198 | 0.01% | ₹39,000 |
| Angel One Nifty Total Market ETFAngel One Mutual Fund | 194 | 0.01% | ₹38,250 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Sun Pharma Advanced Research Company in market cap.
Where the company sits among the companies nearest its size
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Supriya LifescienceSUPRIYA | 6,588 | 33.2 | 5.5 | 22.5 | +28.1% | +11.4% | 18.1% | 21.6% | 0.12% |
 Sanofi IndiaSANOFI | 6,386 | 19.7 | 7.7 | 12.5 | −8.9% | −10.7% | 40.3% | 54.0% | 4.44% |
 Innova CaptabINNOVACAP | 5,650 | 36.1 | 5.2 | 23.1 | +34.5% | +20.4% | 15.3% | 15.0% | 0.20% |
 Senores PharmaceuticalsSENORES | 5,597 | 42.6 | 6.0 | 28.2 | – | – | 15.3% | 13.1% | 0.00% |
 FDCFDC | 5,514 | 18.8 | 2.2 | 16.3 | +3.4% | +8.7% | 12.3% | 11.1% | 1.48% |
 Orchid PharmaORCHPHARMA | 4,930 | – | – | – | +26.2% | – | – | 0.2% | 0.00% |
 IOL Chemicals and PharmaceuticalsIOLCP | 4,818 | 28.7 | 2.7 | 15.3 | +18.6% | +60.1% | 9.6% | 11.8% | 0.61% |
 Novartis IndiaNOVARTIND | 4,505 | 46.1 | 5.5 | 37.7 | +5.4% | −4.9% | 12.2% | 12.2% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
4 Oct · Legal
Aug 2026
13 Aug · General Updates
10 Aug · Board meeting
Sun Pharma Advanced Research Company share price by year
Each calendar year to 2025.Sun Pharma Advanced Research Company share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 134.45 | −33.0% | 202.02 | 112.01 |
| 2024 | 200.55 | −30.1% | 455.30 | 190.33 |
| 2023 | 286.80 | +37.5% | 286.80 | 162.90 |
| 2022 | 208.60 | −27.3% | 344.20 | 174.20 |
| 2021 | 286.90 | +48.1% | 305.25 | 142.15 |
| 2020 | 193.75 | +24.0% | 204.95 | 83.30 |
| 2019 | 156.20 | −16.9% | 200.35 | 113.35 |
| 2018 | 188.05 | −63.0% | 519.35 | 188.05 |
| 2017 | 507.70 | +66.6% | 512.90 | 274.70 |
| 2016 | 304.80 | −10.3% | 397.20 | 247.50 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 173.30 | 174.65 | 167.22 | 171.77 | 171.39 | 7,97,112 | 38.6% |
| 22 Oct 2026 | 178.00 | 178.00 | 171.82 | 173.09 | 174.46 | 6,63,756 | 39.5% |
| 21 Oct 2026 | 185.37 | 186.01 | 176.58 | 179.27 | 179.92 | 8,21,279 | 43.0% |
| 19 Oct 2026 | 190.00 | 191.42 | 184.30 | 185.07 | 186.00 | 3,91,970 | 42.4% |
| 16 Oct 2026 | 189.20 | 190.90 | 186.27 | 188.64 | 188.68 | 4,45,349 | 35.1% |
| 15 Oct 2026 | 192.50 | 193.77 | 187.50 | 188.31 | 190.09 | 5,78,794 | 43.1% |
| 14 Oct 2026 | 189.05 | 198.20 | 189.05 | 191.81 | 194.45 | 13,13,200 | 30.3% |
| 13 Oct 2026 | 185.78 | 190.00 | 182.51 | 189.05 | 186.16 | 6,91,639 | 35.0% |
| 12 Oct 2026 | 188.75 | 190.80 | 183.80 | 184.85 | 186.16 | 5,41,233 | 37.9% |
| 9 Oct 2026 | 188.75 | 192.06 | 184.05 | 185.60 | 186.82 | 8,28,265 | 38.0% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Rights issue history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 16 Mar 2016 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
| 23 Aug 2012 | Rights issue | – | Shareholders were offered new shares. Noted, not adjusted for. |
Each event is noted and not adjusted for.
Company details
- Legal name
- Sun Pharma Advanced Research Company Limited
- NSE symbol
- SPARC
- BSE code
- 532872
- ISIN
- INE232I01014
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Jul 2007
- Face value
- ₹1
- CIN
- L73100GJ2006PLC047837
- Corporate identity number, the registrar of companies' code for it